Abstract-The aim of this work was to examine whether the risk of death i.a. due to haemorrhage into the central nervous system (CNS) is higher during some phases of acute myeloblastic leukaemia (AML), lymphoblastic leukaemia (ALL), and the blastic phase of chronic myelogenous leukaemia (BP) when two important risk factors that worsen the prognosis are simultaneously present: low thrombocytopenia and hyperleukocytosis. Clinical and post-mortem neuropathological examination was performed in 143 patients, aged 17-76 years, who died from AML (80 cases), BP (38), and ALL (25). Periods with co-existence of thrombocytopenia below 25 £ 10 9 per l and hyperleukocytosis above 100 £ 10 9 per l were identi ed after plotting the results and were termed the 'critical period' (CP). The study showed that the risk of death was disproportionatelyhigh during the CP. This nding was obtained in all patient groups, although it involved mainly patients with AML and BP, i.e. leukaemias with the highest frequency of hyperleukocytosis in peripheral blood. It is suggested that the risk of death during the CP is so high because leukaemic cells are a potent synergistic factor to thrombocytopenia in causing CNS haemorrhage. When a CP is detected, hyperleukocytosis and thrombocytopenia should be controlled and treated aggressively: leukapheresis and platelet concentrates should be administered. Patients with CP should not be given packed red blood cells, in order to avoid a further increase in blood viscosity, which is already high due to hyperleukocytosis. In fact, anaemia during the CP should be regarded as a potentially life-saving factor.
INTRODUCTION
Haemorrhage into the central nervous system (CNS) in patients with leukaemia is usually fatal because it is dif cult to control and is frequently very extensive [1, 2] .
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The risk of haemorrhage is particularly high when the platelet count falls below 25 £ 10 9 per l. One underlying cause is thrombocytopenia, resulting from in ltration of the bone marrow by leukaemic cells, but other conditions, such as disseminated intravascular coagulation, shock, infection, chemotherapy, and bone marrow transplantation, may also play an important role in the haemorrhagic event [3 -7] .
Although leukaemic and lymphomatous cells are considered to be responsible for CNS in ltrates rather than as factors facilitating CNS haemorrhage, they should also be taken into account as a risk for bleeding into the CNS [8 -10] . Leukostasis, particularly within the capillary network, may be of some importance in disruption of the vascular wall [11] [12] [13] and in the development of brain oedema [14] . This can explain why the frequency of haemorrhage is highest among patients with myelomonoblastic and acute monoblastic leukaemias, when the aggressiveness of the leukaemic cells against the vessels is notable. Massive intracerebral leukaemic in ltrates are accompanied by local ischaemia and capillary stasis, which are factors promoting haemorrhage [12, 15] . The release of lysokinase from leukaemic cells may directly activate brinolysis and intravascular coagulation [16] . In previous reports and in everyday practice, the two mentioned risk factors of leukaemia are examined separately from each other.
The aim of this work was to examine whether the risk of death i.a. due to haemorrhage into the CNS is signi cantly higher during some phases of acute myeloblastic leukaemia (AML), lymphoblastic leukaemia (ALL), and the blastic phase of chronic myelogenous leukaemia (BP) when two important risk factors of CNS involvement that worsen the prognosis are simultaneously present: low thrombocytopenia and hyperleukocytosis. The clinical signi cance of a better understanding of this problem might be expressed in prevention or treatment procedures in this dangerous constellation of risk factors.
MATERIALS AND METHODS
Clinical and post-mortem neuropathological examination was performed in 143 patients of both sexes, aged 17-76 years (mean 42.6 years), who consecutively died from AML (80 cases), BP (38), and ALL (25). Patients with con rmed disseminated intravascular coagulation were not taken into consideration in the study. AML patients received chemotherapy according to the TAD regimen. ALL patients were treated according to the Hoelzer protocol. Supportive therapy included transfusions of packed red blood cells, platelet concentrates, and blood preparations, and was administered according to generally accepted principles. Platelet and white cell counts in peripheral blood were repeatedly obtained from each patient. 25 £ 10 9 per l was accepted as the critical level of thrombocytopenia and of high risk of haemorrhage into the CNS. On the basis of our previous studies and values given in the literature [11, 12] , we took 100 £ 10 9 per l as the level of leukocytosis critical for leukostasis and perivascular in ltrates in the brain and
